Research Paper Volume 16, Issue 6 pp 5618—5633
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy
Figure 4. Validation of the applicability of the risk model in TCGA-glioma patients with wild-type TERTp. (A) Patients with TERTp-wild-type glioma in the TCGA database were divided into high-risk and low-risk groups based on the median risk score. (B) Survival differences between patients in the high-risk and low-risk groups. (C–E) Diagnostic value of risk models for 1-year, 3-year, and 5-year survival rates. (F) Survival time as a function of risk score for glioma patients with wild-type TERTp in the high-risk and low-risk groups. Green dots represent living cases, and red dots represent dead cases. (G) Heatmap depicting expression levels of HOXC6, WT1, CD70, and OTP in gliomas from patients with wild-type TERTp in the high-risk and low-risk groups.